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Abstract: Chronic obstructive pulmonary disease (COPD) and bronchial asthma are common 
respiratory diseases that are caused by chronic inﬂ  ammation of the airways. Although these 
diseases are mediated by substantially distinct immunological reactions, especially in mild 
cases, they both show increased numbers of neutrophils, increased production of tumor 
necrosis factor-alpha (TNF-α) and poor responses to corticosteroids, particularly in patients 
with severe diseases. These immunological alterations may contribute strongly to airway 
structural changes, commonly referred to as airway remodeling. Microvascular alterations, a 
component of airway remodeling and caused by chronic inﬂ  ammation, are observed and appear 
to be clinically involved in both diseases. It has been well established that vascular endothelial 
growth factor (VEGF) plays important roles in the airway microvascular alterations in mild 
and moderate cases of both diseases, but any role that VEGF might play in severe cases of 
these diseases remains unclear. Here, we review recent research ﬁ  ndings, including our own 
data, and discuss the possibility that TNF-α and its associated CXC chemokines play roles 
in microvascular alterations that are even more crucial than those of VEGF in patients with 
severe COPD or asthma.
Keywords: TNF-α, CXC chemokines, corticosteroid, pulmonary microvessels, COPD, 
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Introduction
Chronic obstructive pulmonary disease (COPD) and bronchial asthma are common 
respiratory diseases that are caused by chronic or excessive inﬂ  ammation of the 
airways.
Chronic inﬂ  ammation of the airways in these diseases is mediated by substantially 
distinct immunological reactions, with different patterns of inﬂ  ammatory cells and 
mediators, particularly in patients with mild to moderate diseases. The inﬂ  ammatory 
process in COPD is characterized by increases in macrophages, neutrophils and CD8+ 
T cells (Grashoff et al 1997; Jeffery 2000; Hogg et al 2004), as well as important 
mediators such as interleukin 8 (IL-8) and tumor necrosis factor-alpha (TNF-α) 
(Chung 2001). On the other hand, the inﬂ  ammatory process in asthma is characterized 
by increased eosinophils, mast cells and type-2 helper T (Th2) cells, which produce 
IL-4, -5 and -13 (Busse and Lemanske 2001).
These immunological differences between COPD and asthma are considered to 
be associated with differences in the efﬁ  cacy of inhaled corticosteroid (ICS) therapy 
as well as airway structural changes (ie, airway remodeling) between these diseases. 
Among the components of airway remodeling, microvascular alterations have been International Journal of COPD 2008:3(4) 620
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increasingly noted in both diseases. ICS is known to be the 
most effective therapy available for treatment of asthma, 
particularly in patients with mild to moderate disease (Barnes 
et al 1998). Indeed, numerous studies showing the effects 
of ICS on bronchial biopsy and bronchoalveolar lavage 
samples in patients with asthma have demonstrated that the 
increased numbers of CD4+ T cells, eosinophils and mast 
cells and increased vascularity seen in this disease are sub-
stantially reduced by ICS (Laitinen et al 1991; Bentley et al 
1996; Chetta et al 2003). In contrast, patients with COPD 
respond poorly to ICS treatment. It is generally assumed 
that neutrophils are less sensitive to corticosteroids than are 
eosinophils and T cells (Schleimer 1990). These differences 
in the responsiveness of activated inﬂ  ammatory cells help 
to explain why ICS treatment has been more beneﬁ  cial for 
patients with asthma than COPD. Furthermore, these differ-
ences in corticosteroid responsiveness between COPD and 
asthma can also be used for differential diagnosis.
However, it has now become evident that these immu-
nological proﬁ  les of both diseases are altered during pro-
gression from mild to severe diseases. In severe COPD, the 
number of macrophages, activated neutrophils, natural killer 
lymphocytes in the subepithelium are further increased in 
comparison with subjects with mild to moderate diseases 
(Di Stefano et al 1998). Furthermore, bronchial inﬂ  amma-
tion in severe COPD is characterized by lower numbers of 
CD3+ and CD8+ T cells in comparison with subjects with 
mild to moderate diseases (Di Stefano et al 2001). These 
ﬁ  ndings show a shift of inﬂ  ammatory proﬁ  les involved in 
severe diseases. On the other hand, some of the common 
features of COPD and asthma, including increased num-
bers of neutrophils, increased amounts of TNF-α and poor 
responses to corticosteroids, are seen in patients with both 
severe cases (Howarth et al 2005; Kamath et al 2005; Berry 
et al 2006; Mann and Chung 2006; Barnes 2007, 2008). 
This not only makes differential diagnosis complicated 
but also has important implications for the development 
of therapeutic strategies for patients with severe COPD 
or asthma.
In this review, we focus on the role of microvessels in the 
development of airway obstructive diseases, including COPD 
and asthma, and discuss how the immunological features 
of patients with severe diseases affect the microvascular 
alterations in both diseases. Notably, this article highlights 
the possible crucial involvement of TNF-α and CXC chemo-
kines, rather than vascular endothelial growth factor (VEGF), 
in the microvascular alterations seen in COPD and asthma, 
particularly in severe cases.
VEGF and microvascular alterations 
in COPD and asthma
Vascular regulation by VEGF
VEGF was originally identiﬁ  ed as a vascular permeability 
factor based on its ability to cause tissue edema (Senger et al 
1993). Subsequently, VEGF has been widely recognized 
as one of the most potent angiogenic factors, mediating 
the growth of new vessels from preexisting ones (Risau 
1997). The process of angiogenesis is a complex and highly 
orchestrated series of multiple events, including proliferation, 
migration, survival and tube formation of vascular endo-
thelial cells. VEGF has several isoforms that are produced 
by alternative splicing of a single VEGF gene (Ferrara et al 
2003) and act via their speciﬁ  c receptors, VEGFR1/Flt-1 
and/or VEGFR2/KDR/Flk-1, on vascular endothelial cells 
(Yancopoulos et al 2000).
VEGF in COPD
Both functional (increased microvascular permeability, 
edema and inﬂ  ammatory cell recruitment) and structural 
(angiogenesis) changes in the airway microvessels are seen in 
chronic airway inﬂ  ammatory conditions. Although microvas-
cular alterations in asthma are well documented, as described 
below, those in COPD have not been fully elucidated yet. An 
early report indicated that the alveolar septa in emphysema 
appear to be remarkably thin and almost avascular (Liebow 
1959). Later, Abman and Voelkel et al demonstrated that 
lung blood vessels actively promote normal alveolar develop-
ment and contribute to the maintenance of alveolar structure 
(Jakkula et al 2000; Kasahara et al 2000; Abman 2001). 
These studies indicated that a reduction in the blood supply 
of the microvessels might induce the destruction of alveolar 
septa. Indeed, VEGF concentration in induced sputum was 
signiﬁ  cantly reduced in emphysema (Kanazawa et al 2003). 
Similarly, VEGFR2 expression was also decreased in total 
lung extracts of emphysema patients (Kasahara et al 2000). 
On the contrary, VEGF concentration in induced sputum 
was signiﬁ  cantly elevated in chronic bronchitis patients, 
although those levels were lower than those in asthmatic 
patients. Similar to the pattern seen in asthmatics, chronic 
bronchitis patients show an inverse correlation between the 
concentration of VEGF and the forced expiratory volume in 
one second (FEV1). In contrast, the concentration of VEGF 
correlated positively with FEV1 in emphysema patients, 
probably due to VEGF-mediated maintenance of the alveolar 
structure. Thus, the VEGF level in the lung is considered to 
explain the pathologies in COPD.International Journal of COPD 2008:3(4) 621
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VEGF in asthma
To date, numerous studies have shown that VEGF is critically 
involved in the microvascular alterations observed in asthma. 
Exaggerated levels of VEGF have been detected in asthmatic 
airways compared with in the airways in normal control 
subjects (Hoshino et al 2001a, b; Asai et al 2002; Kanazawa 
et al 2002; Asai et al 2003; Chetta et al 2005). VEGF levels 
in the airways show a positive correlation with airway inﬂ  am-
mation (Lee and Lee 2001) and correlate inversely with 
lung function (Asai et al 2003), suggesting that VEGF plays 
important roles in the pathogenesis of asthma. In a murine 
model of bronchial asthma, lung-speciﬁ  c and inducible over-
expression of VEGF was shown to enhance not only angio-
genesis, but also Th2 inﬂ  ammation and hyperresponsiveness 
of the airways (Lee et al 2004). Importantly, the biological 
effects of overexpressed VEGF, such as angiogenesis, were 
reversed by cessation of the transgenic VEGF elaboration in 
that murine model, suggesting that the effects of VEGF on the 
development of airway hypervascularity are dependent upon 
its expression level. In humans, ICS treatment was found to 
effectively reduce VEGF production in the airways, thereby 
reducing the submucosal vascularity (Asai et al 2002; Chetta 
et al 2003, 2005; Abdel-Rahman et al 2006; Feltis et al 2007). 
However, it should be noted that these studies were restricted 
to cases of mild to moderate asthma. Therefore, any role of 
VEGF in severe refractory asthma remains unclear.
CXC chemokines and microvascular 
alterations in COPD and asthma
Vascular regulation by CXC chemokines
Chemokines convey speciﬁ  city to the leukocyte recruit-
ment cascade by inducing leukocyte subtypes to adhere to 
endothelium and activate so as to play an essential role in 
the inﬂ  ammatory process. Chemokines are divided into two 
major subfamilies, CXC and CC, based on the position of the 
ﬁ  rst two conserved cysteine residues: the two cysteines are 
separated by a non-conserved amino acid in CXC chemo-
kines, whereas they are adjacent in CC chemokines (Zlotnik 
and Yoshie 2000). CXC chemokines are further subdivided 
into ELR and non-ELR types based on the presence or 
absence of a glutamic acid, leucine and arginine sequence 
adjacent and N-terminal to the CXC motif. Members of the 
CXC chemokines with an ELR-motif include growth-related 
oncogene alpha (Gro-α)/CXC ligand 1 (CXCL1), Gro-
β/CXCL2, Gro-γ/CXCL3, epithelial neutrophil activating 
peptide 78 (ENA78)/CXCL5, granulocyte chemotactic 
protein 2 (GCP2)/CXCL6 and IL-8/CXCL8. These molecules 
act as major chemoattractants for neutrophils. In contrast, 
members of the CXC chemokines without an ELR-motif 
include monokine induced by IFN-γ (MIG)/CXCL9, 
interferon (IFN)-inducible protein 10 (IP-10)/CXCL10 
and IFN-inducible T cell alpha chemoattractant (I-TAC)/
CXCL11, and these chemokines act as chemoattractants 
for Th1 cells.
These two subtypes of CXC chemokines show disparate 
properties regarding angiogenesis and can be divided into 
an angiogenic ELR-positive type and an angiostatic ELR-
negative type. The angiogenic activity of ELR-positive 
CXC chemokines, such as IL-8, is mediated via their com-
mon receptor, CXC chemokine receptor 2 (CXCR2), which 
is expressed on microvascular endothelial cells (Addison 
et al 2000; Heidemann et al 2003). These chemokines are 
thus referred to as “CXCR2 chemokines” throughout this 
manuscript. In contrast, the angiostatic activity of ELR-
negative CXC chemokines, such as IP-10, is mediated via 
their common receptor, CXCR3, which is also expressed on 
microvascular endothelial cells (Lasagni et al 2003). These 
chemokines are thus referred to as “CXCR3 chemokines” 
throughout this manuscript.
The process of angiogenesis is known to be regulated 
by a complex interaction of activators and inhibitors, and 
inappropriate production of these factors may cause aberrant 
angiogenesis. As a matter of fact, a recent report indicated 
the importance of the CXC chemokine-mediated angiogenic/
angiostatic balance in bleomycin-induced pulmonary ﬁ  brosis. 
The study clearly showed that a CXCR3 chemokine, I-TAC, 
inhibits IL-8-mediated angiogenesis (Burdick et al 2005).
CXC chemokines in COPD
In contrast to asthma, CD4+ T cells that accumulate in the 
airways of patients with COPD are mainly Th1 cells produc-
ing IFN-γ (Majori et al 1999; Panina-Bordignon et al 2001). 
CXCR3 chemokines such as IP-10 are induced by IFN-γ 
from a variety of cell types (Sauty et al 1999; Hardaker 
et al 2004), including endothelial cells (Marx et al 2000; 
Matsuda et al 2008a). Furthermore, studies of peripheral 
lung lymphocytes from cigarette smokers with emphysema 
indicated that their CD4+ T cells are not only polarized to 
the Th1 phenotype, but also secreted more CXCR3 chemo-
kines compared to those in the group without emphysema 
(Grumelli et al 2004). Immunoreactivity for IP-10 was 
detected in the airway epithelium (Saetta et al 2002) and 
smooth muscle (Hardaker et al 2004) of COPD patients but 
not in normal control subjects. Furthermore, in response to 
IP-10, but not IFN-γ, lung macrophages secreted matrix International Journal of COPD 2008:3(4) 622
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metalloproteinase-12 (MMP12), a potent elastin-degrading 
enzyme that causes tissue destruction and has been linked 
to emphysema (Grumelli et al 2004). Thus, CXCR3 chemo-
kines are considered to be involved in the pathogenesis of 
COPD, particularly in emphysema.
As described above, these chemokines also act as 
potent anti-angiogenic factors. In addition to reduction of 
VEGF, overproduction of CXCR3 chemokines may pro-
mote avascularity of the emphysema lung (Kanazawa et al 
2003). However, it is evident that IL-8, a proangiogenic 
CXCR2 chemokine, is also predominant in patients with 
COPD (Pesci et al 1998). TNF-α appears to play a role in 
the pathogenesis of COPD (Chung 2001), and the levels 
of TNF-α are further upregulated in severe COPD patients 
(Hacievliyagil et al 2006) and patients experiencing acute 
COPD exacerbation (Aaron et al 2001). Human airway 
smooth muscle cells (Hardaker et al 2004), epithelial cells 
(Sauty et al 1999) and microvascular endothelial cells 
(Matsuda et al 2008a) treated simultaneously with IFN-γ 
and TNF-α demonstrated robust increases in the produc-
tion of CXCR3 chemokines compared with cells treated 
with either stimulus alone. These ﬁ  ndings strongly suggest 
that overproduction of CXCR3 chemokines induced by the 
combination of IFN-γ and TNF-α is more involved in the 
pathogenesis of severe COPD, at least in part through their 
excess anti-angiogenic activity, than is CXCR2 chemokine-
mediated angiogenic activity. Importantly, proliferation and 
tube formation by human lung microvascular endothelial 
cells was almost completely inhibited in the co-presence of 
IFN-γ and TNF-α in vitro, even in the presence of sufﬁ  cient 
amounts of recombinant VEGF (Matsuda et al 2008a). This 
observation is also fully compatible with the pathological 
ﬁ  ndings of avascularity in emphysema. Thus, CXCR3 
chemokines might be involved in the aberrant vascularity, 
which is responsible for destruction of the alveolar septa, 
observed in patients with severe emphysema, as well as their 
chemotactic properties.
As described above, levels of CXCR2 ligands, such as 
IL-8 and ENA78/CXCL5 are elevated in bronchoalveolar 
lavage ﬂ  uid of COPD patients (Pesci et al 1998). These 
chemokines recruit and activate neutrophils via their recep-
tor CXCR2 expressed on neutrophils. Therefore, small 
molecule inhibitors of CXCR2 such as SB225002 are 
likely to be useful for attenuating CXCR2 ligands-mediated 
neutrophilic inﬂ  ammation in the COPD airway (Hay and 
Sarau 2001; Barnes 2003). However, considering especially 
for the CXC chemokines-mediated angiogenic-angiostatic 
balance in the airway, CXCR2 antagonists are likely to be 
more useful for severe asthma than for severe COPD, as 
discussed below.
CXC chemokines in asthma
Although VEGF-mediated airway hypervascularity in 
patients with asthma is responsive to corticosteroid treatment 
(Asai et al 2002; Chetta et al 2003, 2005; Abdel-Rahman 
et al 2006; Feltis et al 2007), several clinical studies have 
also demonstrated that airway hypervascularity is seen in 
fatal (Wilson 2000) and severe corticosteroid-dependent 
asthma (Vrugt et al 2000) and even in patients treated with 
ICS for more than 5 years (Tanaka et al 2003). Of note, 
structural abnormalities of airway remodeling are present 
in children with severe asthma. Tillie-Leblond et al studied 
bronchial biopsies from severe asthma with persistent symp-
toms in two groups of children with or without persistent 
airﬂ  ow obstructive pattern. Persistent obstructive pattern 
was deﬁ  ned as a FEV1 less than 80% of the predicted value 
after a course of systemic corticosteroids and no signiﬁ  cant 
improvement after bronchodilator. They demonstrated that 
an increase in the density of the vascular network was more 
pronounced in children with persistent airﬂ  ow obstruction 
than in children without persistent airﬂ  ow obstruction (Tillie-
Leblond et al 2008). These observations indicate that airway 
hypervascularity in severe asthma is poorly responsive to 
corticosteroid treatment and is clinically involved in lung 
function. Therefore, another possible explanation of the cause 
besides VEGF might be the presence of hypervascularity in 
severely asthmatic airways. Recently, we have shown that, 
only in the presence of TNF-α, IL-4/13 and IFN-γ recipro-
cally regulate angiogenesis by human lung microvascular 
endothelial cells in vitro through autocrine synthesis of 
CXCR2 and CXCR3 chemokines, respectively (Matsuda 
et al 2008a). It should be noted that CXCR2 chemokine-
induced angiogenesis is independent of VEGF. These results 
highlight the importance of TNF-α for VEGF-independent/
CXCR2 chemokine family-dependent angiogenesis. While 
both IL-8 and TNF-α are abundant in the severely asthmatic 
airways (Howarth et al 2005; Berry et al 2006; Mann and 
Chung 2006; Silvestri et al 2006), airway hypervascularity in 
severe asthma might be primarily due to TNF-α and CXCR2 
chemokines rather than mediation by VEGF. Furthermore, 
corticosteroid therapies would offer little hope for improving 
TNF-α/CXCR2 chemokine-associated angiogenesis, 
because corticosteroid has scant effect on TNF-α-induced 
CXCR2 chemokine production by human lung microvas-
cular endothelial cells (Matsuda et al 2008b). Therefore, 
CXCR2 antagonists are likely to be useful for attenuating International Journal of COPD 2008:3(4) 623
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TNF-α/CXCR2 chemokines-mediated hypervascularity in 
addition to blocking chemokine-induced neutrophil chemo-
taxis and activation (Barnes 2007) in patients with severe 
asthma, which are characterized by elevated levels of TNF-α 
and neutrophilic inﬂ  ammation.
Corticosteroid actions in pulmonary 
microvascular endothelial cells
In the context discussed above, TNF-α-associated CXC 
chemokines appear to play critical roles in vascular altera-
tions in both COPD and asthma, especially in severe cases. 
In addition to these structural alterations, TNF-α also plays 
crucial roles in vascular functions by regulating leukocyte 
recruitment into local inﬂ  amed tissues (Kelly et al 2007), 
which is an important step in the development of acute and 
chronic inﬂ  ammatory responses (Carlos and Harlan 1994). 
This recruitment is a dynamic process requiring interactions 
between leukocytes and the vascular endothelium. To that 
end, TNF-α induces endothelial cell expression of various 
molecules, including intercellular adhesion molecule 1 
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), 
that are essential for those interactions (Cotran and Pober 
1990). Recently, we demonstrated that TNF-α-induced 
expressions of  ICAM-1 and VCAM-1 on human lung micro-
vascular endothelial cells were further enhanced by cortico-
steroid treatment (Matsuda et al 2008b). Correspondingly, 
adhesion of eosinophils and neutrophils to these cells was 
also enhanced by corticosteroid treatment, suggesting that 
instead of inhibiting the recruitment of inﬂ  ammatory cells 
into local inﬂ  amed tissues, ICS therapies actually promote 
their adhesion, probably via upregulation of cell-surface 
expression of ICAM-1 and VCAM-1 on the endothelium. 
Indeed, in severe asthma, a highly signiﬁ  cant correlation was 
found between the total number of vessels and the vessels 
expressing ICAM-1 in biopsy specimens (Vrugt et al 2000), 
which supports the hypothesis that ICS therapies are not 
effective in reducing ICAM-1 expression on the endothelium. 
While TNF-α-induced IP-10 expression in microvascular 
endothelial cells is further enhanced by corticosteroid treat-
ment (Matsuda et al 2008b), ICS therapies might not be 
effective in curing the avascularity observed in emphysema 
patients. Together, ICS therapies offer little expectation for 
improving TNF-α-mediated pulmonary microvascular altera-
tions, including CXCR2 chemokine-mediated angiogenesis, 
CXCR3 chemokine-mediated avascularity and inﬂ  ammatory 
cell recruitment. Moreover, these microvascular alterations 
mediated by TNF-α might be clinically associated with the 
development of COPD and also asthma.
TNF-α is a major therapeutic target in chronic inﬂ  ammatory 
diseases including rheumatoid arthritis and Crohn’s diseases 
(Feldmann and Maini 2003). Recently, clinical trials of anti-
TNF-therapy have demonstrated good improvement in lung 
function and airway hyperresponsiveness in severe refractory 
asthma (Howarth et al 2005; Berry et al 2006). Thus, it is now 
recognized that anti-TNF therapies are likely to become an 
important treatment option for patients with refractory asthma 
(Holgate et al 2006). The effectiveness of anti-TNF therapies 
in such patients may be at least partly due to the prevention 
of TNF-α-activated vascular inﬂ  ammation. However, a 
clinical study has demonstrated that subjects with moderate 
to severe COPD did not beneﬁ  t from treatment with anti-TNF 
therapy (Rennard et al 2007). It is currently unclear why the 
anti-TNF therapy is more effective for severe asthma than 
for severe COPD. Although further studies are needed to 
elucidate the pathological roles in TNF-α of severe COPD 
and asthma, respectively, differences in increased number 
of blood vessels, which are major targets of TNF-α, in the 
airway between these diseases (ie, avascularity in severe 
COPD and hypervascularity in severe asthma) may reﬂ  ect 
to the efﬁ  cacy of anti-TNF therapy.
Possibility of microvessel-targeted 
treatment options in COPD 
and asthma
The impact of corticosteroids on pulmonary microvascular 
endothelial cells is apparently distinct from that on other 
airway structural cells, including epithelial cells, smooth 
muscle cells and fibroblasts, in which TNF-α-induced 
expressions of chemokines and cellular adhesion molecules 
are signiﬁ  cantly downregulated by corticosteroid treatment 
(Spoelstra et al 2000; Issa et al 2007; Newton et al 2007; 
Matsuda et al 2008b). Increased amounts of TNF-α and poor 
responses to corticosteroids are common features observed in 
both COPD and severe asthma. Therefore, TNF-α-mediated 
responses of pulmonary microvessels, such as inﬂ  ammatory 
cell recruitment into inﬂ  amed tissues and inﬂ  ammatory 
chemokine expression, may at least partially explain the 
corticosteroid refractoriness in these diseases. In this context, 
as a new therapeutic strategy for patients with severe COPD 
or asthma, the near future holds the possibility of direct 
microvessel-targeted topical treatment options.
ICAM-1 is a potential candidate molecule for targeted 
treatment of patients with severe COPD or asthma. Although 
there have not been any clinical trials of anti-ICAM-1 therapy 
for patients with severe COPD or asthma, in a rat model of 
extrinsic asthma, administration of monoclonal antibody International Journal of COPD 2008:3(4) 624
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to ICAM-1 significantly attenuated both the early and 
late responses of bronchial asthma (Nagase et al 1995). In 
ICAM-1-deﬁ  cient mice, signiﬁ  cant inhibition of lung tissue 
eosinophil recruitment (Broide et al 1998) and airway hyper-
reactivity (Hatﬁ  eld et al 1997) were observed after allergen 
challenge. ICAM-1 is expressed not only on the inﬂ  amed 
endothelium but also on inﬂ  amed ﬁ  broblasts and epithelium 
in the airways. Respiratory viruses are a major cause of exac-
erbations of both COPD and asthma, and the most prevalent 
viruses detected during exacerbations are the rhinoviruses 
(Nicholson et al 1993; Johnston et al 1995; Seemungal et al 
2000; Rohde et al 2003). Since ICAM-1 is a major receptor 
for rhinovirus (Staunton et al 1989), anti-ICAM-1 therapy 
might be effective in preventing rhinovirus-induced exacer-
bations of these diseases in addition to attenuating inﬂ  amma-
tory cell recruitment into local inﬂ  amed tissues.
Alternatively, as described above, CXCR3 and CXCR2 
might be potential candidate molecules for targeted treatment 
of patients with severe COPD and asthma, respectively. 
Anti-CXCR3 therapy might bring about improvement of 
CXCR3 chemokine-induced avascularity in addition to 
attenuating Th1 inﬂ  ammation in emphysema patients. In 
contrast, anti-CXCR2 therapy might lead to improvement of 
CXCR2 chemokine-induced hypervascularity in addition to 
neutrophilic inﬂ  ammation in severe asthmatics.
Conclusions
COPD and asthma are chronic inﬂ  ammatory diseases of 
the airways, and characteristic structural alterations in the 
airways are observed in each disease, including microvas-
cular alterations. These microvascular alterations caused 
by chronic inﬂ  ammation appear to be clinically involved in 
both diseases. Although the type of inﬂ  ammation is quite 
different between COPD and asthma, especially in patients 
with mild to moderate disease, increased amounts of TNF-α, 
neutrophilic inﬂ  ammation and poor responses to corticoste-
roids are the common features in patients with severe COPD 
or asthma.
Figure 1 presents an overview of microvascular alterations 
in pulmonary inﬂ  ammatory diseases discussed in this review. 
In COPD, VEGF concentration in chronic bronchitis patients 
is signiﬁ  cantly elevated, although those levels are lower than 
those in asthmatic patients. However, increased numbers 
of microvessels (ie, angiogenesis) in the airway of COPD 
patients have not been established. Some COPD patients 
with emphysema show rather reduced production of VEGF, 
Figure 1 An overview of microvascular alterations in pulmonary inﬂ  ammatory diseases.International Journal of COPD 2008:3(4) 625
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resulting in the destruction of alveolar septa. In contrast, in 
mild to moderate asthma, increased production of VEGF in 
the airway is critically involved in angiogenesis, but such 
VEGF-mediated angiogeneis in the asthmatic airway is effec-
tively reversed by corticosteroid treatment. In patients with 
severe COPD or severe asthma, TNF-α, which is a pleiotropic 
proinﬂ  ammatory cytokine that exerts its biological effects 
mainly by acting on the vascular endothelium, is abundant 
in the airway. Only in the presence of TNF-α, IL-4/13 and 
IFN-γ reciprocally regulate angiogenic-angiostatic balance 
through autocrine synthesis of CXCR2 and CXCR3 chemo-
kines, respectively. Corticosteroid therapies would offer little 
hope for improving TNF-α/CXCR2 chemokine-associated 
angiogenesis, and thus hypervascularity in severe asthma 
might be primarily due to TNF-α and CXCR2 chemokines 
rather than mediation by VEGF. On the other hand, TNF-α-
associated overproductions of CXCR3 chemokines in severe 
emphysema might be involved in the avascularity in alveolar 
septa, in addition to reduction of VEGF. Moreover, TNF-α 
also plays crucial roles directly in vascular functions by regu-
lating leukocyte recruitment into local inﬂ  amed tissues, but 
corticosteroid therapies would enhance these inﬂ  ammatory 
responses on the microvessels rather than inhibit them.
Thus, TNF-α and CXC chemokines can be surmised to be 
critically associated with microvascular alterations in patients 
with severe pulmonary inflammatory diseases. Further 
studies are required to examine whether CXCR3/CXCR2 
chemokines play roles in the attenuation and development of 
pulmonary angiogenesis in patients with severe COPD and 
asthma, respectively. Nevertheless, there is the possibility of 
microvessel-targeted treatment options in the near future for 
these patients, whereas ICS therapies offer little expectation 
for improvement of these microvascular alterations mediated 
by TNF-α and CXC chemokines.
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